Dr Eva Szegezdi

Contact

• Email: eva.szegezdinuigalway.ie
• Phone: + 353 91 495037 
• Postal address: Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway, University Road, Galway, Ireland

Career History

• Lecturer in Biochemistry, 2011 - present
• SFI Starting Investigator Research Grant awardee, 2009-2013
• Postdoctoral researcher, Cell Stress and Apoptosis Research Group, NUI, Galway, 2001-2009
• Ph.D. University of Debrecen, Hungary, 2000
• M.Sc. University of Debrecen, Hungary, 1996

Research Interests

• mechanism of death receptor activation
• development of novel therapeutics targeting death receptor-mediated signal transduction
• development of methods to predict tumour response to apoptosis-inducing therapeutics

Selection of key publications:

1. Szegezdi E, van der Sloot AM, Mahalingam D, O'Leary L, Cool RH, Muñoz IG, Montoya G, Quax WJ, de Jong S, Samali A and Serrano L. (2012) Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics. 11(3):M111.013730.

2. Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ and Samali A. (2011) Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med. 15(10):2216-31.

3. Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, de Jong S and Nawrocki ST. (2011) Targeting TRAIL towards the clinic. Curr Drug Targets. 12(14):2079-90.

4. Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, Sjollema K, Stricher F, Cool RH, Samali A, Serrano L and Quax WJ. (2010) Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 21;1:e83.

5. Mahalingam D, Natoni A, Keane M, Samali A and Szegezdi E. (2010) Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer. 102(4):754-64.

6. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A and Szegezdi E (2009) Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. British J Cancer. 100:1415-24.

7. Szegezdi E, O'Reilly A, Davy Y, Vawda R, Taylor DL, Murphy M, Samali A and Mehmet H. (2009) Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med. 13(11-12):4409-14.

8. Reis CR^#, Szegezdi E^#, van der Sloot AM^#, Natoni A, Tur V, Cool RH, Samali A, Serrano L and Quax WJ (2009) Enhancement of anti-tumour properties of rhTRAIL by affinity increase towards both its death receptors. Biochemistry. 48: 2180-91.^#these authors contributed equally

9. Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treatment Rev. 35:280-8.

10. Mylotte LA, Duffy AM, Murphy M, O’Brien T, Samali A, Barry F and Szegezdi E (2008) Metabolic Flexibility Permits MSC Survival in an Ischemic Environment. Stem Cells 26: 1325-36.

11. Szegezdi E, Cahill S, Meyer M, O’Dwyer M, Samali A (2006) TRAIL sensitization by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. British J Cancer, 94: 398 – 406.

12. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Samali A, Serrano L and Quax WJ. (2006) Computational design of a DR5 receptor selective TRAIL variant. PNAS, 103: 8634–8639.

Patents

1. Szegezdi E, Mahalingam D, Natoni A and Samali A (2008) Treatment of proliferative disorders with TRAIL. (UK Patent Application No. 0818649.6)

2. van der Sloot AM, Tur V, Szegezdi E, Samali A, Serrano L, Quax W (2007) New design of DR4 selective variants. (GB-0723059.2)

3. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Samali A, Serrano L, Quax W (2003) Improved cytokine design (WO2005056596)

Current lab members:

Postdoctoral fellows:
Grainne Gernon (B.A. in Natural Sciences (Biochemistry), Trinity College Dublin, Ph.D. in Molecular and Clinical Medicine, University of Edinburgh,UK)
Anne Doyle (M.Sc. in Bioinformatics, Dublin City University, Ph.D. in Virology, University College Dublin)

Graduate students:
Paul O’Reilly (B.Sc., Pharmacology and Therapeutics, National University of Ireland, Galway).
Anna McCormick (B.Sc. in Genetics, University College Dublin, Ireland).
Tamas Sessler (B.Sc., Analytical Biochermistry, University of Debrecen, Hungary).
Mairead Reidy (B.Sc., in Biochemistry, University College Cork, MSc. in Neuropharmacology, National University of Ireland, Galway).

Previous lab members
Dr. Marianne van Dijk (2007-2011) now at Karolinska Institutet, Sweden.
Dr. Lynda O’Leary (2007-2012) now at BBCRC, Institute of Cancer Research, London.
Dr. Louise Mylotte (2005-2008) now lecturer at St. Angela’s College, National University of Ireland, Galway in Ireland.
Dr Devalingam Mahalingam (2005-2008) now at Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, USA

Lectures/ courses
Programme co-ordinator, MSc in Cancer Biology
Module co-ordinator: 1^st year medical degree programme Metabolism, Nutrition and Health (MD140)

• Disclaimer
• Privacy
• Copyright
• Accessibility